Clinical Trials Core

临床试验核心自U54启动以来一直很活跃，并系统地 并通过维持、改进和扩大其基本使命而逐步推进。核心助力 1)针对癌症临床试验中的少数人和未得到充分服务的患者，2)教育 血液学/肿瘤学研究员和3)对少数民族和未得到充分服务的患者的问题进行研究 癌症。总体而言，Core已将大量少数族裔和未得到充分服务的患者纳入临床试验 并为这些患者提供了故障保险公立医院通常无法提供的机会。《核心》 维护完整的临床试验资源，包括管理支持、IRB支持、数据收集 以及管理、病人导航、研究护理支持和秘书协助。U54之前的版本 支持，6名患者进入NGH进行临床试验。在区别上，在核心的历史上，我们 已有638名患者参加了临床试验，其中约50%是少数族裔(非裔美国人和 西班牙裔)。总的应收率是所有筛查患者的22%。曾接受治疗的患者的应收率 根据他们的疾病部位和阶段以及符合资格标准的人进行的研究显著增加了53%。在我们的网站上， 与大多数患者相比，少数族裔患者同意进行临床试验的可能性并不低。

The Clinical Trials Core has been active since the initiation of the U54 and has systematically and progressively advanced by sustaining, improving and extending its basic mission. The Core contributes to 1) patient targeting especially minority and underserved accrual on cancer clinical trials, 2) education of hematology/oncology fellows and 3) research into the issues of the minority and underserved patient with cancer. Overall, the Core has entered large numbers of minority and underserved patients onto clinical trials and given these patients opportunities that are usually not available at fail-safe public hospitals. The Core maintains a complete resource for clinical trials including administrative support, IRB support, data collection and management, patient navigation, research nursing support and secretarial assistance. Prior to U54 support, 6 patients were entered on clinical trials at the NGH. In distinction, over the history of the Core, we have accrued 638 patients to clinical trials of which approximately 50% are minorities (African American and Hispanic). The overall accrual rate is 22% of all patients screened. The accrual rate of patients who had a study available for their disease site and stage and who met eligibility criteria is a remarkatjie 53%. At our site, minority patients are no less likely to consent to clinical trials compared to majority patients.